Uncategorized

KRAS drugmakers take another, better swing at lung cancer

Published

on

SAN DIEGO — In early cuts of data, the next iteration of KRAS drugs for lung cancer appears to bear more promise than the first.

KRAS mutations drive around a quarter of all cancer cases and …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version